(1) Sequoia Sciences' Annual Report 2016.(2) 2014 National Disease and Therapeutic Index (NDTI, IMS Health, Plymouth Meeting, PA). ICD9: 595.0; 595.9; 599.0; 597.8.(3) Sanchez et al. Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60(5):2680-3; Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Estocolmo: Centro Europeo para la Prevención y el Control de las Enfermedades; 2015.(4) Urologist UTI Survey. Sequoia Sciences, Inc. y HRA Research; 2010.(5) Trevino et al. Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms. J Antimicrob Chemother. 2015;70(12):3397-3400.(6) Han et al. Epidemiology of Carbapenem-Resistant Klebsiella Pneumoniae in a Network of Long-Term Acute Care Hospitals. Clinical Infectious Diseases. 2017;64(7):839-44.(7) Ventola CL. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics. 2015;40(4):277-83; World Health Organization Fact Sheets. [citado el 3 de noviembre de 2016]; disponible en http://www.who.int/mediacentre/factsheets/fs194/en/ [http://www.who.int/mediacentre/factsheets/fs194/en/].
CONTACTO: CONTACTO: Jennifer Westphal, FleishmanHillard, 816.512.2241,jennifer.westphal@fleishman.com
